BR112014026334A2 - forma de dosagem de grande volume de infusão de gencitabina e conjunto - Google Patents

forma de dosagem de grande volume de infusão de gencitabina e conjunto

Info

Publication number
BR112014026334A2
BR112014026334A2 BR112014026334A BR112014026334A BR112014026334A2 BR 112014026334 A2 BR112014026334 A2 BR 112014026334A2 BR 112014026334 A BR112014026334 A BR 112014026334A BR 112014026334 A BR112014026334 A BR 112014026334A BR 112014026334 A2 BR112014026334 A2 BR 112014026334A2
Authority
BR
Brazil
Prior art keywords
dosage form
gemcitabine
large volume
volume dosage
volume infusion
Prior art date
Application number
BR112014026334A
Other languages
English (en)
Other versions
BR112014026334A8 (pt
BR112014026334B1 (pt
Inventor
B Namdeo Alok
Ganorkar Kirti
Kane Prashant
Kumarth Samarth
B Bhowmick Subhas
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48325397&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014026334(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of BR112014026334A2 publication Critical patent/BR112014026334A2/pt
Publication of BR112014026334A8 publication Critical patent/BR112014026334A8/pt
Publication of BR112014026334B1 publication Critical patent/BR112014026334B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
    • B65D85/30—Containers, packaging elements or packages, specially adapted for particular articles or materials for articles particularly sensitive to damage by shock or pressure
    • B65D85/42—Containers, packaging elements or packages, specially adapted for particular articles or materials for articles particularly sensitive to damage by shock or pressure for ampoules; for lamp bulbs; for electronic valves or tubes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

resumo “forma de dosagem de grande volume de infusão de gencitabina e conjunto” a presente invenção refere-se a uma forma de dosagem de grande volume de infusão de gencitabina, compreendendo uma solução estável em grande volume de gencitabina ou o seu sal farmaceuticamente aceitável em um veículo aquoso preenchido em um recipiente de grande volume de infusão, em que a solução está pronta para ser infundida. ?? ?? ?? ?? 1/1
BR112014026334-5A 2012-04-27 2013-04-26 Forma de dosagem de infusão de gencitabina e conjunto que compreende a mesma BR112014026334B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1334/MUM/2012 2012-04-27
IN1334MU2012 2012-04-27
PCT/IN2013/000281 WO2013171763A1 (en) 2012-04-27 2013-04-26 Ready to be infused gemcitabine solution

Publications (3)

Publication Number Publication Date
BR112014026334A2 true BR112014026334A2 (pt) 2017-06-27
BR112014026334A8 BR112014026334A8 (pt) 2021-06-15
BR112014026334B1 BR112014026334B1 (pt) 2022-04-12

Family

ID=48325397

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014026334-5A BR112014026334B1 (pt) 2012-04-27 2013-04-26 Forma de dosagem de infusão de gencitabina e conjunto que compreende a mesma

Country Status (16)

Country Link
US (1) US9241948B2 (pt)
EP (1) EP2656848B2 (pt)
JP (1) JP6159567B2 (pt)
KR (1) KR101716215B1 (pt)
CN (3) CN109077995A (pt)
AU (1) AU2013261012B2 (pt)
BR (1) BR112014026334B1 (pt)
CA (1) CA2871061C (pt)
ES (1) ES2537294T5 (pt)
MX (1) MX357935B (pt)
PL (1) PL2656848T5 (pt)
PT (1) PT2656848E (pt)
RU (1) RU2621144C2 (pt)
SI (1) SI2656848T2 (pt)
WO (1) WO2013171763A1 (pt)
ZA (1) ZA201408502B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9064577B2 (en) 2012-12-06 2015-06-23 Micron Technology, Inc. Apparatuses and methods to control body potential in memory operations
JP2015000869A (ja) * 2013-06-18 2015-01-05 サムヤン バイオファーマシューティカルズ コーポレイション 有機溶媒無含有ゲムシタビン水溶液組成物
US10098813B2 (en) * 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
JP6033931B2 (ja) * 2015-07-30 2016-11-30 サムヤン バイオファーマシューティカルズ コーポレイション 有機溶媒無含有ゲムシタビン水溶液組成物
US10114999B1 (en) 2016-12-02 2018-10-30 Koupon Media, Inc. Using dynamic occlusion to protect against capturing barcodes for fraudulent use on mobile devices
EP3860575A4 (en) * 2018-10-04 2022-03-16 Race Oncology Ltd. METHOD FOR PREPARING AND ADMINISTRING BISANTRENE FORMULATIONS
WO2021028842A1 (en) * 2019-08-13 2021-02-18 Hetero Healthcare Limited A stable ready-to-use injectable composition of gemcitabine or its salt and methods for producing same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135498A (en) * 1990-04-02 1992-08-04 Kam Robert J Controlled release infusion device
US20050031679A1 (en) * 1998-03-27 2005-02-10 Clemens Unger Method for producing liposomal formulations of active ingredients
US6743523B1 (en) * 2000-03-16 2004-06-01 Baxter International Inc. Multiple layer film of a new non-PVC material
CN1181829C (zh) * 2000-11-03 2004-12-29 中国人民解放军军事医学科学院附属医院 吉西他滨溶液制剂
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
DE10323279A1 (de) * 2003-05-21 2004-12-16 Stada Arzneimittel Ag Gebrauchsfertige Gemcitabin-Lösungen
US20060046964A1 (en) * 2004-09-02 2006-03-02 Andre Morneau Pharmaceutical formulations and methods
US20060089329A1 (en) * 2004-10-22 2006-04-27 Edgar Schridde Ready-to-use gemcitabine solution concentrates
US20060089328A1 (en) * 2004-10-22 2006-04-27 Edgar Schridde Ready-to-use gemcitabine solutions
DE102004063347A1 (de) * 2004-12-23 2006-07-13 Stada Arzneimittel Ag Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate
CN1302782C (zh) * 2005-01-17 2007-03-07 北京京卫燕康药物研究所有限公司 盐酸吉西他滨溶液型注射剂
CN101088492B (zh) * 2006-06-12 2012-02-22 齐鲁制药(海南)有限公司 盐酸吉西他滨稳定的过饱和溶液及其制备方法
US8563022B2 (en) * 2006-10-11 2013-10-22 Board Of Regents Of The University Of Texas System Particles for cell targeting
CN101185654A (zh) 2007-12-11 2008-05-28 常州安孚立德药业技术有限公司 一种盐酸吉西他滨或吉西他滨组合物
ES2536208T3 (es) * 2008-03-07 2015-05-21 Onxeo Dk, Branch Of Onxeo S.A., France Métodos de tratamiento que emplean infusión continua prolongada de Belinostat
WO2011000811A2 (en) 2009-06-30 2011-01-06 Novartis Ag Organic compounds
JP5563528B2 (ja) * 2010-06-29 2014-07-30 高田製薬株式会社 ニコチン酸アミドを含有するゲムシタビン凍結乾燥製剤
JP2012017308A (ja) 2010-07-09 2012-01-26 Nipro Corp ゲムシタビン水溶液製剤

Also Published As

Publication number Publication date
JP2013231029A (ja) 2013-11-14
EP2656848B2 (en) 2018-09-19
ES2537294T5 (es) 2018-12-10
CN109077995A (zh) 2018-12-25
KR101716215B1 (ko) 2017-03-27
PL2656848T3 (pl) 2015-10-30
BR112014026334A8 (pt) 2021-06-15
RU2621144C2 (ru) 2017-05-31
ES2537294T3 (es) 2015-06-05
MX357935B (es) 2018-07-31
CA2871061A1 (en) 2013-11-21
US20130288994A1 (en) 2013-10-31
AU2013261012A1 (en) 2014-11-13
ZA201408502B (en) 2015-11-25
SI2656848T2 (sl) 2019-04-30
KR20150014438A (ko) 2015-02-06
CN113577019A (zh) 2021-11-02
BR112014026334B1 (pt) 2022-04-12
RU2014147388A (ru) 2016-06-20
PL2656848T5 (pl) 2019-02-28
JP6159567B2 (ja) 2017-07-05
AU2013261012B2 (en) 2017-02-02
PT2656848E (pt) 2015-07-01
WO2013171763A1 (en) 2013-11-21
CN104254319A (zh) 2014-12-31
CA2871061C (en) 2017-06-20
SI2656848T1 (sl) 2015-07-31
EP2656848A1 (en) 2013-10-30
EP2656848B1 (en) 2015-04-08
US9241948B2 (en) 2016-01-26
MX2014013101A (es) 2015-01-26

Similar Documents

Publication Publication Date Title
BR112014026334A2 (pt) forma de dosagem de grande volume de infusão de gencitabina e conjunto
BR112013008005A2 (pt) composição farmacêutica kpiquida pronta para uso para adminidtração parental a um indivíduo
GT201500312A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
BR112015026325A2 (pt) dosagem oral de compostos glp-1
GT201300235A (es) Uso de 2,3-dihidroimidazo (1,2-c) quinazolinas sustituidas
BR112015023523B8 (pt) Composições farmacêuticas e recipiente de forma de dosagem única
PH12016500720A1 (en) Stable formulation of insulin glulisine
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
BR112016002770A2 (pt) sal de hemissulfato de ácido 5,10-metileno-(6r)-tetra-hidrofólico
GT201400003A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
BR112015027477A8 (pt) bolus, seus usos, e kit
EP3042652A4 (en) Use of composition containing ferrous amino acid chelate in preparation of anti-cancer medicament
AR093632A1 (es) Tratamiento de cafe soluble
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
UY34076A (es) Composición farmacéutica que contiene volasertib en dosificación mejorada y sus usos contra tumores sólidos avanzados
CL2016000026A1 (es) Nuevos derivados de azabencimidazol
TWD165895S (zh) 包裝用容器
BR112015023481A8 (pt) projeto de perfil de liberação de fármaco de controle via composição de lipossomo em ambos os compartimentos aquosos e não-aquosos
CL2013002193A1 (es) Uso de un producto que comprende macitentano o una sal del mismo en combinacion con un agente alquilante o un inhibidor mitotico para preparar un medicamento util en el tratamiento de glioma maligno.
Mijovic et al. Red blood cell alloimmunization in sickle cell disease-prevalence and trends: a single-center cross-sectional study from United Kingdom.
CL2016000397A1 (es) Tratamiento contra el cáncer
MX2016006377A (es) Un medicamento inhalable.
GEP201706742B (en) Glycogen-based water solubility enhancers
MX2014014839A (es) Terapias sinergicas de cannabidiol con hipotermia para neuroproteccion.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: SUN PHARMACEUTICAL INDUSTRIES LTD (IN)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/04/2013, OBSERVADAS AS CONDICOES LEGAIS.